Nonlinear relationship between cardiometabolic index and bone mineral density in U.S. adults: the mediating role of percent body fat
September 28, 2024 / Cardiometabolic / Body Fat / Bone Density / Lipid Metabolism / NHANES Osteoporosis Study
A study using NHANES data revealed a nonlinear relationship between cardiometabolic index (CMI) and lumbar spine bone mineral density (BMD). Increased CMI correlates with lower BMD, with body fat percentage mediating this effect, highlighting CMI’s relevance in osteoporosis risk assessment.
Expression of Intelectin-1, also known as Omentin-1, is related to clinical phenotypes such as overweight, obesity, insulin resistance, and changes after bariatric surgery
September 27, 2024 / Intelectin-1 / Odmentin-1 / Obesity Biomarkers / Insulin Resistance / Bariatric Surgery Effects
Intelectin-1 (Omentin-1) expression, primarily from visceral adipose tissue, is linked to obesity, insulin resistance, and inflammation. Its levels vary with adipose tissue function and improve after bariatric surgery, suggesting its role in metabolic regulation.
Impacts of social determinants on cardio-kidney-metabolic disease vary greatly across US
September 27, 2024 / Social Determinants of Health / Cardio-kidney-metabolic Disease / Regional Health Disparities / Food Insecurity
A study using geographically weighted models revealed that social determinants of health, like food insecurity and education, impact cardio-kidney-metabolic mortality rates differently across U.S. regions, emphasizing the need for region-specific health policies.
Yoyo dieting alters gut health, driving weight regain and inflammation
September 23, 2024 / Yoyo Dieting / Gut Health / Weight Regain / Microbiota / Gut Inflammation / Obesity / Satiety Hormones
Yoyo dieting alters gut microbiota, reducing satiety hormones and increasing inflammation, leading to weight regain. These changes affect gut health and energy balance, highlighting the need for targeted therapies to prevent weight cycling and promote long-term weight maintenance.
Childhood obesity rates are surging worldwide
September 27, 2024 / Childhood Obesity Epidemic / Pediatric Hypertension / Diabetes / Public Health Solutions for Obesity
Childhood obesity has nearly doubled globally since 1990, leading to serious health issues like hypertension and diabetes. Experts emphasize a multifaceted approach involving physical activity, reduced ultra-processed foods, and public health efforts to combat this growing epidemic.
Weight-loss surgery may preserve kidney health more effectively than GLP-1 drugs
September 27, 2024 / Bariatric Surgery / Kidney Health / Obesity / Chronic Kidney Disease / Metabolic Changes / Type 2 Diabetes / Kidney Protection
Bariatric surgery significantly reduces the progression of kidney disease in patients with obesity and diabetes, outperforming GLP-1 drugs. The surgery induces metabolic changes that lower hunger and protect kidney health by improving diabetes control.
Inhibition of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis
September 27, 2024 / Oxalate Overproduction / MASH / Liver Health / Metabolic Dysfunction
Researchers identified hepatic oxalate overproduction as a key factor in metabolic dysfunction-associated steatohepatitis (MASH). Targeting oxalate by inhibiting LDHA or overexpressing AGXT improved lipid metabolism and reduced inflammation, offering a potential therapeutic approach for MASH treatment.
Global burden of metabolic dysfunction-associated steatotic liver disease attributable to high fasting plasma glucose in 204 countries and territories from 1990 to 2021
September 27, 2024 / MASLD / High Fasting Plasma Glucose / Liver Disease
The global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) attributable to high fasting plasma glucose (HFPG) has increased significantly from 1990 to 2021, with variations by region, age, and sex. Targeted health interventions are crucial for addressing this rising trend.
Ultra-processed foods are silently altering your metabolism, scientists warn
September 26, 2024 / Ultra-processed foods / Metabolic Biomarkers / Adolescents’ Metabolism / Gut Microbiome Disruption / Metabolic Disorders Risks
Ultra-processed foods significantly alter metabolism in adolescents and young adults, impacting biomarkers linked to detoxification, amino acid metabolism, and lipid pathways. These metabolic changes, notably through gut microbiome disruption, increase risks of obesity and metabolic disorders.
HIV and Aging: Evaluating Metabolic Deficits and Immune Dysfunction
September 26, 2024 / HIV / Aging / Metabolic Dysfunction / Immune System Therapy / Antiretroviral Treatment / Inflammation in HIV
Researchers are exploring how aging, HIV, and metabolic dysfunction impact immune cell function. The study aims to identify therapeutic interventions targeting metabolic pathways, using existing FDA-approved compounds to improve immune function in people with HIV.
The Link Between Overactive Bladder and Metabolic Syndrome
September 26, 2024 / Overactive Bladder / Obesity / Metabolic Syndrome / Hypertension / Bladder Health
A large study confirms a strong link between overactive bladder (OAB) and metabolic syndrome (MetS), especially obesity, hypertension, and hyperlipidemia. Clinicians should consider addressing metabolic imbalances when treating female patients with OAB.
Simple Blood Test May Predict Cardiometabollic Complications For Children With Obesity: Study
September 26, 2024 / Cardiometabolic Complications / Obesity / Childhood Obesity
Scientists from the University of Copenhagen have detected lipid biomarkers in children and teenagers with obesity that indicate an increased risk of developing type 2 diabetes, liver and heart disease as adults. A one-year lifestyle intervention lowered the levels of these lipid biomarkers, which demonstrates the importance of early intervention for children with obesity.
New Published Data Show Reproducibility and Utility of Perspectum’s MRI in Patients With Metabolic Liver Disease
September 26, 2024 / Liver Disease / Quantitative MRI / MASH Noninvasive Diagnosis / Liver Biopsy Alternatives
Recent studies confirm that Perspectum’s quantitative MRI effectively detects and monitors metabolic liver disease, offering a safer alternative to liver biopsy. This noninvasive approach predicts treatment response, supporting its use in clinical trials and patient care for MASH.
Social Risk Profile Drives Cardiovascular-Kidney-Metabolic Disparities in Adults
September 26, 2024 / Cardiovascular-kidney-metabolic disparities / CKM Syndrome / CKM Health
A study revealed that poor social risk profiles significantly increase the likelihood of advanced cardiovascular-kidney-metabolic (CKM) syndrome. Routine social risk screening and targeted interventions for disadvantaged groups are recommended to address CKM disparities in the U.S.
Lilly and Novo Spend Billions to Expand Obesity Pipelines Beyond GLP-1s
September 25, 2024 / Hypothalamic Inflammation / Obesity / Diabetes / Insulin Resistance / Hypothalamic Obesity
Eli Lilly and Novo Nordisk are investing billions in acquisitions and partnerships to expand obesity treatment pipelines beyond GLP-1s. Their strategies focus on innovative therapies, including RNA, small molecules, and metabolic modifiers to maintain market dominance.
Novel regulator of glucose transport in adipose tissue discovered
September 25, 2024 / PICALM / Glucose Transport / Insulin Sensitivity in Fat Cells / Type 2 Diabetes Treatment / Obesity / Glucose Metabolism
Researchers identified PICALM as a novel regulator of glucose transport and insulin signaling in adipose tissue. Reduced PICALM expression improves insulin sensitivity and glucose uptake, making it a promising therapeutic target for treating type 2 diabetes and obesity.
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
September 25, 2024 / MASH / Fibrosis Treatment / AI / Digital Pathology / NASH / Liver Health
Galmed’s Phase 3 trial of Aramchol demonstrated significant anti-fibrotic effects in patients with MASH and fibrosis. Using AI-based digital pathology and traditional histology, Aramchol 300mg BID improved fibrosis, positioning it as a promising therapeutic for MASH.
Targeted obesity programs reduce lipid-related heart disease risk in children
September 24, 2024 / Childhood Obesity / Lipid Profile / Cardiometabolic Risk / Obesity / Cardiovascular Disease / Weight Management in Children
A study revealed that targeted weight management programs in obese children significantly reduce cardiometabolic risks, including lipid abnormalities like ceramides and triglycerides. These changes lower the risk of cardiovascular disease, type 2 diabetes, and fatty liver.
A week of intense cycling may burn abdominal fat without major weight loss, study finds
September 23, 2024 / Cycling / Fat Loss / Visceral Fat Reduction / Cardiometabolic Health / Abdominal Fat / Exercise / Weight Loss
A study found that one week of intense cycling in middle-aged men reduced visceral and abdominal fat without significant weight loss. Despite increased energy intake, participants improved their cardiometabolic profiles and maintained high cardiorespiratory fitness.